GlassScriptPhysician profile
Brooke A Benton
NPI 1871905505
$10,938.02
in general payments reported to CMS, 2019-2025
38 companies · $2,354 in 2025
The $2,354 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $980 · 2021: $836 · 2022: $1,566 · 2023: $2,108 · 2024: $2,388 · 2025: $2,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,850.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,987.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,631.47 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $1,357.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $708.94 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $677.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $629.84 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $459.09 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $435.69 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.63 | 2019-2025 | Jardiance, Synjardy |
| Ardelyx, INC. | $305.26 | 2024-2025 | Ibsrela |
| Allergan, INC. | $229.62 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $195.22 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $194.04 | 2019-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $192.64 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $153.00 | 2020-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $146.76 | 2024-2025 | |
| Gilead Sciences, INC. | $141.09 | 2019-2024 | |
| Dexcom, INC. | $140.14 | 2022-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $108.84 | 2024-2025 | Auvelity, Symbravo |
| Pharmacosmos Therapeutics INC. | $101.24 | 2022 | |
| Exact Sciences Corporation | $91.70 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $83.30 | 2019-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $81.03 | 2020-2025 | Zoryve |
| Sumitomo Pharma America, INC. | $76.63 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $62.14 | 2021-2023 | Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $53.58 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $47.78 | 2021-2024 | Linzess |
| Shield Therapeutics INC | $45.43 | 2023-2025 | Accrufer |
| Horizon Therapeutics Plc | $43.86 | 2023 | Krystexxa |
| Philips North America LLC | $41.77 | 2024 | (Cm9) Amb Mon & Diag Und, (Ak6) Vest Therapy |
| Hologic Sales and Service, LLC | $37.70 | 2021-2025 | Aptima |
| Janssen Pharmaceuticals, INC | $32.79 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.99 | 2022 | |
| Currax Pharmaceuticals LLC | $25.85 | 2021-2022 | |
| Nuvasive, INC. | $24.37 | 2022 | |
| Amarin Pharma, INC. | $20.32 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.55 | 2024 | Nuzyra |
| Nalpropion Pharmaceuticals LLC | $16.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Benton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.